Northfield PolyHeme priority review status brings April user fee goal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Northfield Laboratories' PolyHeme application carries a user fee goal date of April 30 following FDA's designation of the BLA for priority review status. PolyHeme could be the first blood substitute on the market. The human hemoglobin-based red blood cell substitute seeks an indication for treatment of life-threatening RBC loss when an oxygen-carrying fluid is required and red blood cells are not available. The BLA is supported by a Phase III randomized, double-blind trial in 720 trauma patients (1"The Pink Sheet" DAILY, Aug. 15, 2007)
You may also be interested in...
Northfield Labs Eyes First Half 2008 For PolyHeme BLA Submission
The company will seek a priority review for the investigational red blood cell substitute.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.